KRONOS BIO INC. - COM

0,9601

27-ноября-24 16:00:04

15 мин. задержка

Акции

+0,0951

+10,99%

Сегодняшний диапазон

0,9200 - 0,9899

ISIN

N/A

Источник

NASDAQ

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

09 янв 2023 07:00:04 Источник Nasdaq GlobeNewswire
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

11 дек 2022 10:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

07 дек 2022 16:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences

22 ноя 2022 16:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

08 ноя 2022 16:10:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

08 ноя 2022 16:05:02 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

12 окт 2022 04:04:45 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

06 сен 2022 16:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

22 авг 2022 08:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

16 авг 2022 16:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results

04 авг 2022 16:05:02 Источник Nasdaq GlobeNewswire
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

10 июн 2022 03:04:36 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences

01 июн 2022 16:05:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference

17 май 2022 07:00:02 Источник Nasdaq GlobeNewswire
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

12 май 2022 10:23:18 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results

04 май 2022 16:05:02 Источник Nasdaq GlobeNewswire
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

08 апр 2022 13:07:03 Источник Nasdaq GlobeNewswire
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022

08 мар 2022 17:08:22 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference

01 мар 2022 07:00:02 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results

24 фев 2022 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.